feed,title,long_url,short_url
Benzinga,Aldeyra Therapeutics Announces Publication Of Phase 2 Clinical Trial Of Reproxalap In Allergen Chamber Model,https://benzinga.com/news/22/02/25334962/aldeyra-therapeutics-announces-publication-of-phase-2-clinical-trial-of-reproxalap-in-allergen-chamb,https://bit.ly/348LiSu
Benzinga,Allegro Microsystems Sees Q4 2022 Revenue $193M-$197M Vs $191.96M Est; Sees Adj. EPS $0.20-$0.21 Vs $0.19 Est,https://benzinga.com/news/22/02/25334925/allegro-microsystems-sees-q4-2022-revenue-193m-197m-vs-191-96m-est-sees-adj-eps-0-20-0-21-vs-0-19-es,https://bit.ly/3L0SfFW
Benzinga,Microvast Confirms Revenue Guidance For FY21 Will Be Within Previously Announced Range Of $145M-$155M vs $146.68M Est,https://benzinga.com/news/22/02/25333882/microvast-confirms-revenue-guidance-for-fy21-will-be-within-previously-announced-range-of-145m-155m,https://bit.ly/3J033SV
